ES2073394T3 - Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares. - Google Patents

Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares.

Info

Publication number
ES2073394T3
ES2073394T3 ES88108793T ES88108793T ES2073394T3 ES 2073394 T3 ES2073394 T3 ES 2073394T3 ES 88108793 T ES88108793 T ES 88108793T ES 88108793 T ES88108793 T ES 88108793T ES 2073394 T3 ES2073394 T3 ES 2073394T3
Authority
ES
Spain
Prior art keywords
antibody constructs
antibody component
bifunctional antibody
cellular populations
selectively destroy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88108793T
Other languages
English (en)
Inventor
Stuart F Schlossman
Charles F Scott Jr
John M Lambert
Walter A Blattler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2073394T3 publication Critical patent/ES2073394T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

UN CONJUNTO DE ANTICUERPOS HETERODIMERO BIFUNCIONAL COMPRENDIENDO (A) UN COMPONENTE DE ANTICUERPO CELULAR ANTI-DIANA UNIDO A B) UN COMPONENTE DE ANTICUERPO ANTI-LINFOCITO DONDE EL COMPONENTE DE ANICUERPO ANTI-LINFOCITO ES ESPECIFICO PARA LINFOCITOS ACTIVADOS. UN CONJUGADO MOLECULAR DE UNION SUPERFICIAL CELULA/ANTICUERPO BIFINCIONAL Y UN COMPONENTE ANTICUERPO HIBRIDO BIFUNCIONAL COMPRENDIENDO LAS ETAPAS QUE SE DETALLAN AN LA INVENCION. SE DESCRIBE DETALLADAMENTE EL METODO DE SELECCION DESTRUCTIVA DE POBLACIONES DE CELULAS DIANA.
ES88108793T 1987-06-10 1988-06-01 Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares. Expired - Lifetime ES2073394T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6020587A 1987-06-10 1987-06-10

Publications (1)

Publication Number Publication Date
ES2073394T3 true ES2073394T3 (es) 1995-08-16

Family

ID=22028021

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88108793T Expired - Lifetime ES2073394T3 (es) 1987-06-10 1988-06-01 Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares.

Country Status (5)

Country Link
EP (1) EP0294703B1 (es)
JP (1) JPS643128A (es)
AT (1) ATE122238T1 (es)
DE (1) DE3853740T2 (es)
ES (1) ES2073394T3 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
WO1989006544A1 (en) * 1988-01-15 1989-07-27 Centocor, Inc. Heteroligating antibodies and therapeutic uses thereof
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5173293A (en) * 1989-02-23 1992-12-22 Becton Dickinson And Company Anti-T-cell antibodies as adjuvants
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
FR2649119A1 (fr) * 1989-06-30 1991-01-04 Centre Nat Rech Scient Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
RU2272644C2 (ru) 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US20030149246A1 (en) * 2002-02-01 2003-08-07 Russell John C. Macromolecular conjugates and processes for preparing the same
EP1622645B1 (en) * 2002-04-23 2013-10-23 Roger Williams Hospital Compositions and methods for stem cell delivery
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP4494977B2 (ja) 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
DK1699822T3 (da) 2003-12-30 2008-08-04 Merck Patent Gmbh IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
WO2005063808A1 (en) 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
ATE443724T1 (de) 2004-01-22 2009-10-15 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ATE465176T1 (de) 2004-12-09 2010-05-15 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
DK2444424T3 (en) 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
CA2635623C (en) 2005-12-30 2015-02-17 Michael Super Anti-cd19 antibodies with reduced immunogenicity
ES2384055T3 (es) 2005-12-30 2012-06-28 Merck Patent Gmbh Variantes de la interleucina-12p40 con estabilidad mejorada
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
EP2491056B1 (en) 2009-10-22 2021-09-15 Universiteit Twente Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering
DK3411398T3 (da) 2016-02-05 2024-06-24 Orionis Biosciences BV Målrettede terapeutiske midler og anvendelse heraf
JP7657014B2 (ja) 2016-03-07 2025-04-04 ブイアイビー ブイゼットダブリュー Ｃｄ２０結合単一ドメイン抗体
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
CA3052523A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences Nv Targeted chimeric proteins and uses thereof
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
AU2019215440B2 (en) 2018-02-05 2025-12-04 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
US4882424A (en) * 1987-05-11 1989-11-21 Dana-Farber Cancer Institute, Inc. Activation antigen

Also Published As

Publication number Publication date
EP0294703A2 (en) 1988-12-14
ATE122238T1 (de) 1995-05-15
JPS643128A (en) 1989-01-06
EP0294703A3 (en) 1990-06-27
EP0294703B1 (en) 1995-05-10
DE3853740T2 (de) 1995-11-09
DE3853740D1 (de) 1995-06-14

Similar Documents

Publication Publication Date Title
ES2073394T3 (es) Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares.
FI990875A0 (fi) CD4-spesifinen yhdistelmävasta-aine
BG31496A3 (bg) Метод за получаване на 4-амино-5-алкил-сулфонил ортоанизамиди
BG45701A3 (bg) Метод за получаване на алфа-хетероциклично заместени толунитрили
ES2153444T3 (es) Anticuerpos contra interleucina-4 mamifera, y peptidos utiles como antigenos en su produccion.
ATE113845T1 (de) Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.
ES2035317T3 (es) Un metodo para la deteccion y el analisis de celulas hematopoyeticas en una muestra.
DE59307572D1 (de) Holzbelag, insbesondere holzbodenbelag
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
IT8519102A0 (it) Composizione di organopolisilossano polimerizzabile in un elastomero e relativo impiego.
ES2097747T3 (es) Molecula de adhesion intercelular 2 y sus ligandos de union.
FI902143A7 (fi) HIV-peptidit, keinotekoiset HIV-antigeenit ja immunomäärityspakkaukset
ES2124250T3 (es) Anticuerpo especifico para un antigeno tumoral.
ES2124215T3 (es) Unos anticuerpos monoclonales al fiv y polipeptidos relacionados y su metodo de obtencion.
ES2181871T3 (es) Inmunoensayo de numeracion celular.
ES2090052T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y uso.
BG35327A3 (bg) Метод за получаване на пиридоксинови производни
BG33296A3 (bg) Метод за получаване на производни на 4- дезацетил- винкалевкобластин с- 3- карбоксихидразид
DE68912462D1 (de) Xanthenfarbstoffe.
ES2042461T1 (es) Producto y procedimiento para el te\ido oxidativo del cabello.
ATE361363T1 (de) Impfstoff, der peroxiredoxin enthält
DE69328779D1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
ES2052913T3 (es) Ensayo inmunoquimico en cuanto al factor estimulante de colonias de granulocitos-macrofagos.
ATE90790T1 (de) Verfahren zur herstellung einer festphasenmatrix.
ES2130703T3 (es) Conjugados de benzodiazepinas y proteinas y su utilizacion para la determinacion inmunologica de benzodiazepinas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 294703

Country of ref document: ES